RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Alterity Therapeutics - Stock

Alterity Therapeutics Stocks 2024

Alterity Therapeutics Stocks

2.43 B

Ticker

ATH.AX

ISIN

AU0000043945

WKN

A2PHDZ

In 2024, Alterity Therapeutics had 2.43 B outstanding stocks, a 0.91% change from the 2.41 B stocks in the previous year.

The Alterity Therapeutics Stocks history

YEARNUMBER OF STOCKS (undefined AUD)
20232.43
20222.41
20211.7
20200.89
20190.62
20180.53
20170.53
20160.53
20150.5
20140.43
20130.34
20120.29
20110.25
20100.23
20090.2
20080.17
20070.14
20060.13
20050.12
20040.08

Alterity Therapeutics shares outstanding

The number of shares was Alterity Therapeutics in 2023 — This indicates how many shares 2.428 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Alterity Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Alterity Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Alterity Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Alterity Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Alterity Therapeutics Aktienanalyse

What does Alterity Therapeutics do?

Alterity Therapeutics Ltd is an Australian company specializing in the discovery and development of therapeutics for neurodegenerative diseases. The company's history dates back to 1997 when it was established under the name Prana Biotechnology Limited. Alterity Therapeutics' business model is based on the research of protein aggregates responsible for neurodegenerative diseases. The company primarily focuses on developing drugs targeting the breakdown of these protein aggregates to minimize the effects of diseases such as Parkinson's, Alzheimer's, and Huntington's. The company has several divisions specializing in various aspects of product development, including preclinical research, clinical development, and commercial marketing. Alterity Therapeutics has several products in various stages of development. One of its leading products is PBT434, a drug that aims to prevent protein aggregates in the brain and target the treatment of Parkinson's disease. The drug has already been tested in clinical trials and has shown promising results. In addition to PBT434, the company also has other promising drugs in development, including PBT519, targeting the treatment of Alzheimer's disease, and PBT2, targeting the treatment of Huntington's disease. Alterity Therapeutics aims to minimize the impact of neurodegenerative diseases and improve the quality of life for millions of patients worldwide. The company collaborates with leading medical and academic institutions to develop innovative therapeutics that meet the needs of patients and clinicians. Overall, Alterity Therapeutics offers a promising pipeline of drugs that could play a significant role in the treatment of neurodegenerative diseases. The company has become a major player in the industry and has the potential to make a significant impact in the fight against these serious illnesses. Alterity Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Alterity Therapeutics's Shares Outstanding

Alterity Therapeutics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Alterity Therapeutics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Alterity Therapeutics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Alterity Therapeutics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Alterity Therapeutics Stock

How many stocks are there of Alterity Therapeutics?

The current number of stocks of Alterity Therapeutics is 2.43 B undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Alterity Therapeutics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Alterity Therapeutics evolved in recent years?

The number of shares of Alterity Therapeutics has increased by 0.91% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Alterity Therapeutics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Alterity Therapeutics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Alterity Therapeutics pay?

Over the past 12 months, Alterity Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Alterity Therapeutics is expected to pay a dividend of 0 AUD.

What is the dividend yield of Alterity Therapeutics?

The current dividend yield of Alterity Therapeutics is .

When does Alterity Therapeutics pay dividends?

Alterity Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Alterity Therapeutics?

Alterity Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Alterity Therapeutics?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Alterity Therapeutics located?

Alterity Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Alterity Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Alterity Therapeutics from 6/16/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 6/16/2024.

When did Alterity Therapeutics pay the last dividend?

The last dividend was paid out on 6/16/2024.

What was the dividend of Alterity Therapeutics in the year 2023?

In the year 2023, Alterity Therapeutics distributed 0 AUD as dividends.

In which currency does Alterity Therapeutics pay out the dividend?

The dividends of Alterity Therapeutics are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Alterity Therapeutics

Our stock analysis for Alterity Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Alterity Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.